NVO News

Novo Nordisk A/S - share repurchase programme

Alpha Thalassemia (US, EU4, UK, and Japan) Market Insights, Epidemiology, and Forecasts 2022-2025 & 2025-2036

Global Weight Loss and Obesity Management Market | 12.8% CAGR Growth Trajectory | Asia Pacific, North America Lead | Novo Nordisk, Eli Lilly, Medtronic Drive Integrated Care Evolution

2026 Top Trends in Snacks and Confectionery: GLP-1 Medications Such as Ozempic has Heightened the Significance of the "Snack As the New Meal" Trend

Choose Health Launches Comprehensive At-Home GLP-1 Monitoring Panels for Ozempic, Wegovy and Mounjaro Users

Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU

92% Awareness, 38% Interest Signal Next Wave of GLP-1 Adoption, Reach3 Insights Study Finds

Novi Weight Loss GLP-1 Program (2026): What 50,000 People Searching This Brand Need to Know Before Enrolling

Novo Nordisk's Wegovy® HD available now nationwide

Novo Nordisk A/S – Share repurchase programme